Design Therapeutics (NASDAQ:DSGN) Releases Earnings Results

Design Therapeutics (NASDAQ:DSGN) posted its quarterly earnings results on Monday. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04, Zacks reports.

Design Therapeutics Stock Down 1.0 %

Shares of NASDAQ:DSGN opened at $4.87 on Tuesday. The firm has a market capitalization of $275.74 million, a price-to-earnings ratio of -5.73 and a beta of 1.77. The stock’s 50 day moving average is $4.87 and its 200-day moving average is $5.36. Design Therapeutics has a twelve month low of $2.45 and a twelve month high of $7.77.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.